AI Article Synopsis

  • The snake venom rhodocytin activates platelets via a newly identified receptor, CLEC-2, independent of established receptors like integrin alpha2beta1 and GPVI.
  • CLEC-2 contains a specific tyrosine residue that gets phosphorylated during platelet activation by rhodocytin and is essential for signal transduction.
  • The activation process involves multiple signaling proteins, including Syk and PLCgamma2, making CLEC-2 a key player in a novel platelet activation pathway.

Article Abstract

The snake venom rhodocytin has been reported to bind to integrin alpha2beta1 and glycoprotein (GP) Ibalpha on platelets, but it is also able to induce activation independent of the 2 receptors and of GPVI. Using rhodocytin affinity chromatography, we have identified a novel C-type lectin receptor, CLEC-2, in platelets that confers signaling responses to rhodocytin when expressed in a cell line. CLEC-2 has a single tyrosine residue in a YXXL motif in its cytosolic tail, which undergoes tyrosine phosphorylation upon platelet activation by rhodocytin or an antibody to CLEC-2, but not to collagen, thrombin receptor agonist peptide (TRAP), or convulxin. Tyrosine phosphorylation of CLEC-2 and other signaling proteins by rhodocytin is inhibited by the Src family kinase inhibitor PP2. Further, activation of murine platelets by rhodocytin is abolished in the absence of Syk and PLCgamma2, and partially reduced in the absence of LAT, SLP-76, and Vav1/Vav3. These findings define a novel signaling pathway in platelets whereby activation of CLEC-2 by rhodocytin leads to tyrosine phosphorylation of its cytosolic tail, binding of Syk and initiation of downstream tyrosine phosphorylation events, and activation of PLCgamma2. CLEC-2 is the first C-type lectin receptor to be found on platelets which signals through this novel pathway.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-05-1994DOI Listing

Publication Analysis

Top Keywords

tyrosine phosphorylation
16
c-type lectin
12
lectin receptor
12
platelet activation
8
receptor clec-2
8
cytosolic tail
8
clec-2
7
rhodocytin
7
activation
6
platelets
5

Similar Publications

Tyrosine kinase inhibitors (TKIs) serve to inhibit the phosphorylation cascade that usually leads to abnormal processes such as vascular leakage and tumorigenesis. Within retinal diseases specifically, dysregulation of the vascular endothelial growth factor receptor tyrosine kinases can lead to age-related macular degeneration and diabetic macular edema. These diseases have a growing prevalence and are leading causes of vision loss.

View Article and Find Full Text PDF
Article Synopsis
  • Incessant ovulation contributes to ovarian high-grade serous carcinomas (HGSC), which primarily arise from the fallopian tube epithelium (FTE), and receptor tyrosine kinase (RTK) ligands play a key role in this process.
  • A study investigated follicular fluid exosomes from women undergoing in vitro fertilization to identify RTK ligands and their impact on FTE cells, using various RTK inhibitors.
  • The findings revealed that FF exosomes were rich in transformative abilities and essential EGFR ligands, promoting cell growth and migration, indicating their significant contribution to HGSC development.
View Article and Find Full Text PDF

Background: Yes-associated protein 1 (YAP1) regulates the survival, proliferation, and stemness of cells, and contributes to the development of metabolic dysfunction associated fatty liver disease (MAFLD). However, the regulatory role of intestinal YAP1 in MAFLD still remains unclear.

Methods: Terminal ileal specimens were used to compare intestinal YAP1 activation in patients with and without MAFLD.

View Article and Find Full Text PDF

Missense mutations in the EPHA1 receptor tyrosine kinase have been identified in Alzheimer's patients. To gain insight into their potential role in disease pathogenesis, we investigated the effects of four of these mutations. We show that the P460L mutation in the second fibronectin type III (FN2) domain drastically reduces EPHA1 cell surface localization while increasing tyrosine phosphorylation of the cell surface localized receptor.

View Article and Find Full Text PDF

Discovery of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia.

Eur J Med Chem

December 2024

Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, China. Electronic address:

FMS-like tyrosine receptor kinase 3 (FLT3) mutations, the most common genetic alterations found in acute myeloid leukemia (AML) patients, have been pursued as an ideal drug discovery target for the AML therapy. Taking compound 2 as lead, a series of pyridine derivatives bearing 1,2,3-triazole moiety were rationally designed and synthesized. The bioassays confirmed that these derivatives exerted potent antileukemia effects, and compound 12y was found to be the most potent one.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!